Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TST001 · 1 trial · 4 indications
Characterization of TST001 safety profile including frequency and severity of adverse events that are related to treatment.
As measured by number of participants experiencing dose related toxicity (DLT) in each escalating cohort
Characterization of TST001 + Nivolumab safety profile including frequency and severity of adverse events that are related to treatment.
Characterization of TST001 + Nivolumab + mFOLFOX6 safety profile including frequency and severity of adverse events that are related to treatment.
Characterization of TST001 + Gemcitabine + albumin-bound paclitaxel safety profile including frequency and severity of adverse events that are related to treatment.
| Arm | Type | Description |
|---|---|---|
| Part A Q2W | EXPERIMENTAL | Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, multiple dose levels will be tested. |
| Part A Q3W | EXPERIMENTAL | Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg, and multiple dose levels will be tested. |
| Part B Cohort A | EXPERIMENTAL | Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma. |
| Part B Cohort B | EXPERIMENTAL | Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies. |
| Part B Cohort C | EXPERIMENTAL | Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma. |
| Name | Type | Description |
|---|---|---|
| TST001 | DRUG | TST001 is a humanized IgG1 monoclonal antibody. |
| Nivolumab Injection [Opdivo] | DRUG | Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies |
| mFOLFOX6 | DRUG | mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin. |
| Gemcitabine | DRUG | Chemotherapy medication |
| Albumin-Bound Paclitaxel | DRUG | Chemotherapy medication |
Inclusion Criteria: * Male or female ≥ 18 years. * Patients with histologically or cytologically confirmed, locally advanced or metastatic solid tumors. Part A only: \* Patients must be: a) progressed after standard therapies, b) intolerant of standard therapies, or c) with a tumor type without s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
TST001 is an investigational small molecule being developed for the treatment of advanced cancer, including gastric cancer, gastroesophageal-junction cancer, and pancreatic cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.
TST001 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The drug is currently in Phase 1 clinical trials for advanced cancer.
TST001 is in Phase 1 clinical development. It is an investigational drug being studied in a single active clinical trial for advanced or metastatic solid tumors. The drug has not been approved by the FDA and remains in clinical testing.
TST001 is being evaluated in a Phase 1 clinical trial with the identifier NCT04396821. This trial is assessing the safety and tolerability of TST001 in patients with advanced or metastatic solid tumors, including gastric, gastroesophageal-junction, and pancreatic cancers. The trial is active but not recruiting participants.
TST001 is a distinct investigational drug candidate developed by Bristol-Myers Squibb. No alternative names for TST001 have been reported in the clinical trial information. It is a small molecule being studied for the treatment of advanced cancer.